Low-Dose DOACs Reduce VTE Risk in Transplant-Ineligible Multiple Myeloma: Insights from the BENEFIT Trial
Journal of Thrombosis and Haemostasis (JTH) has shared a post on LinkedIn:
“Thromboembolism in transplant-ineligible multiple myeloma patients on triplet/quadruplet therapy: a post hoc analysis of the BENEFIT trial
In this phase 3 trial of 257 patients with transplant-ineligible newly diagnosed multiple myeloma, the 6-month cumulative incidence of VTE was 4.8%. Among prophylaxis strategies, low-dose DOACs significantly reduced VTE risk compared to heparin or aspirin. Proteinuria ≥0.44 g/L and monoclonal protein ≥22 g/L emerged as strong independent risk factors for VTE. Findings highlight DOACs as a potentially superior prophylaxis option in this high-risk population.”
Title: Thromboembolism in transplant-ineligible multiple myeloma patients on triplet/quadruplet therapy: a post hoc analysis of BENEFIT trial
Authors: Emilie Chalayer, Corinne Frere, Elisabeth Daguenet, Thomas Lecompte, Bernard Tardy, Ilhame Bounouara, Manon Sapet, Arthur Bobin, Stephanie Harel, Olivier Decaux, Karim Belhadj, Cyrille Touzeau, Margaret Macro, Mohamad Mohty, Philippe Moreau, Jill Corre, Hervé Avet–Loiseau, Lionel Karlin, Thierry Facon, Aurore Perrot, Cyrille Hulin, Salomon Manier, Laurent Frenzel, Xavier Leleu
Read the full paper here.
Find similar posts on Hemostasis Today.
-
Jul 23, 2026, 22:20Thrombus NETs Predict Long-Term Ischemic Stroke Recurrence – JTH
-
Jul 23, 2026, 21:16Applications Still Open for the 13th ESO Edinburgh Stroke Research Workshop – European Stroke Organisation
-
Jul 23, 2026, 20:46Grace Choung: A Novel CFHR5 Copy Number Variant in Postpartum Atypical HUS
-
Jul 23, 2026, 20:10Mohammad Alzoubi: One Month of Dual Antithrombotic Therapy After PCI Was Non-Inferior to 12 Months
-
Jul 23, 2026, 20:08Ahmed Bennis: Calcitriol Replenishment May Mitigate Ischemic Risk in MASLD
-
Jul 23, 2026, 20:06Mitsuaki Sawano: Can Cardiovascular Risk Prediction Models Developed in One Population be Reliably Applied to Another?
-
Jul 23, 2026, 20:05Abdul Muqtadir Abbasi: Hemostasis Isn’t About Memorizing Factor Numbers – It’s About Recognizing Patterns
-
Jul 23, 2026, 19:40Maureen Macharia: How Apixaban Transformed Modern Anticoagulation
-
Jul 23, 2026, 19:30Jordan Agay: Why We Need to Track the Neurological Costs of Anemia